Journal of Thrombosis and Thrombolysis

, Volume 47, Issue 1, pp 67–72 | Cite as

Interaction between tissue factor pathway inhibitor-2 gene polymorphisms and environmental factors associated with coronary atherosclerosis in a Chinese Han

  • Hairong Zhou
  • Yanjuan Che
  • Xiuhua FuEmail author
  • Hong Wei
  • Xiuying Gao
  • Yanxuan Chen
  • Shaopeng Zhang


To investigate the association of single nucleotide polymorphisms (SNPs) within tissue factor pathway inhibitor-2 (TFPI-2) gene polymorphisms and additional gene–environment interaction with coronary atherosclerosis risk. Generalized multifactor dimensionality reduction (GMDR) was used to screen the best interaction combination among 4 SNPs, smoking and alcohol drinking. Logistic regression was performed to investigate association between 4 SNPs within TFPI-2 gene and coronary atherosclerosis risk. Coronary atherosclerosis risk was significantly higher in carriers with the A allele of rs34489123 within TFPI-2 gene than those with GG genotype (GA+AA versus GG), adjusted OR (95% CI) = 1.70 (1.20–2.31), and was also higher in carriers with the G allele of rs4264 within TFPI-2 gene than those with AA genotype (AG+GG versus AA), adjusted OR (95% CI) = 1.62 (1.21–2.11). GMDR model shown the best models for gene–environment interaction were rs34489123 and smoking after adjusting the covariates, which scored 10 out of 10 for cross-validation consistency and 0.0010 for the sign test. Heavy LD was found for SNPs rs34489123 and rs59805398 (D’ value was more than 0.8). Compared to control individuals, the AG haplotypes appeared to be significantly associated with increased coronary atherosclerosis risk, OR (95% CI) = 1.73 (1.22–2.32). We found that the A allele of rs34489123 and the G allele of rs4264 within TFPI-2 gene, interaction between rs34489123 and smoking and AG haplotypes were all associated with increased coronary atherosclerosis risk.


Alcohol drinking Coronary atherosclerosis Tissue factor pathway inhibitor-2 Single nucleotide polymorphisms Interaction Smoking 



We thank the investigators and staffs from Longhua District Central Hospital and Mudanjiang second People’s Hospital, and all the partners who help us in the process of this study. Hairong Zhou and Yanjuan Che contributed equally to this work.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Mannarino E, Pirro M (2008) Molecular biology of atherosclerosis. Clin Cases Miner Bone Metab 5:57–62Google Scholar
  2. 2.
    Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109(23 Suppl 1):SIII–S27Google Scholar
  3. 3.
    Hansson GK, Robertson AK, Söderberg–Nauclér C (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1:297–329CrossRefGoogle Scholar
  4. 4.
    Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U (1989) Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9:579–592CrossRefGoogle Scholar
  5. 5.
    Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695CrossRefGoogle Scholar
  6. 6.
    Cooper R, Cutler J, Desvigne-Nickens P, Fortmann SP, Friedman L, Havlik R, Hogelin G, Marler J, McGovern P, Morosco G, Mosca L, Pearson T, Stamler J, Stryer D, Thom T (2000) Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 102(25):3137–3147CrossRefGoogle Scholar
  7. 7.
    Rollin J, Iochmann S, Blechet C, Hube F, Regina S, Guyetant S, Lemarie E, Reverdiau P, Gruel Y (2005) Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 92:775–783CrossRefGoogle Scholar
  8. 8.
    Zhao B, Luo X, Shi H, Ma D (2011) Tissue factor pathway inhibitor-2 is downregulated by ox-LDL and inhibits ox-LDL induced vascular smooth muscle cells proliferation and migration. Thromb Res 128:179–185CrossRefGoogle Scholar
  9. 9.
    Xu Z, Maiti D, Kisiel W, Duh EJ (2006) Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. Arterioscler Thromb Vasc Biol 26:2819–2825CrossRefGoogle Scholar
  10. 10.
    Ivanciu L, Gerard RD, Tang H, Lupu F, Lupu C (2007) Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol 27:310–316CrossRefGoogle Scholar
  11. 11.
    Dong Y, Tan Q, Tao L, Pan X, Pang L, Liang W, Liu W, Zhang W, Li F, Jia W (2015) Hypermethylation of TFPI2 correlates with cervical cancer incidence in the Uygur and Han populations of Xinjiang, China. Int J Clin Exp Pathol 8(2):1844–1854Google Scholar
  12. 12.
    Zhao BL, Liu HY, Ni HC, Luo X, Li J, Jin B, Zhu J, Li Y, Shen W, Shi H (2012) Changes of plasma tissue factor and tissue factor pathway inhibitor 2 levels in elderly patients with acute coronary syndrome. Shanghai Med 35:779–783Google Scholar
  13. 13.
    Yu J, Liu RL, Luo XP, Shi HM, Ma D, Pan JJ, Ni HC (2015) Tissue factor pathway inhibitor-2 gene polymorphisms associate with coronary atherosclerosis in Chinese population. Medicine (Baltimore) 94(42):e1675CrossRefGoogle Scholar
  14. 14.
    Li YF, Hsiao YH, Lai YH, Chen YC, Chen YJ, Chou JL, Chan MW, Lin YH, Tsou YA, Tsai MH, Tai CK (2015) DNA methylation profiles and biomarkers of oral squamous cell carcinoma. Epigenetics 10(3):229–236CrossRefGoogle Scholar
  15. 15.
    Chen JJ, Wang AQ, Chen QQ (2017) DNA methylation assay for colorectal carcinoma. Cancer Biol Med 14(1):42–49CrossRefGoogle Scholar
  16. 16.
    Arakawa N, Kobayashi H, Yonemoto N, Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y, Hirahara F, Hirano H, Miyagi E (2016) Clinical significance of tissue factor pathway inhibitor 2, a serum biomarker candidate for ovarian clear cell carcinoma. PLoS ONE 11(10):e0165609CrossRefGoogle Scholar
  17. 17.
    Pan JJ, Shi HM, Luo XP, Ma D, Li Y, Zhu J, Liang W, Mu JG, Li J (2011) Recombinant TFPI-2 enhances macrophage apoptosis through upregulation of Fas/FasL. Eur J Pharmacol 654:135–141CrossRefGoogle Scholar
  18. 18.
    Pan J, Ma D, Sun F, Liang W, Liu R, Shen W, Wang H, Ji Y, Hu R, Liu R, Luo X, Shi H (2013) Over-expression of TFPI-2 promotes atherosclerotic plaque stability by inhibiting MMPs in apoE-/- mice. Int J Cardiol 168:1691–1697CrossRefGoogle Scholar
  19. 19.
    Siegling S, Thyzel E, Glahn J, Kleesiek K, Götting C (2006) Analysis of sequence variations in the promoter region of the human tissue factor pathway inhibitor 2 gene in apoplectic patients and blood donors. Ann Hematol 85:32–37CrossRefGoogle Scholar
  20. 20.
    Hube F, Reverdiau P, Iochmann S, Cherpi-Antar C, Gruel Y (2003) Characterization and functional analysis of TFPI-2 gene promoter in a human choriocarcinoma cell line. Thromb Res 109:207–215CrossRefGoogle Scholar
  21. 21.
    Mino K, Nishimura S, Ninomiya S, Tujii H, Matsumori Y, Tsuchida M, Hosoi M, Koseki K, Wada S, Hasegawa M, Sasaki R, Murakami-Yamaguchi Y, Narita H, Suzuki T, Miyata N, Mizukami T (2014) Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2). Biosci Biotechnol Biochem 78:1010–1017CrossRefGoogle Scholar
  22. 22.
    Zawadzki C, Chatelain N, Delestre M, Susen S, Quesnel B, Juthier F, Jeanpierre E, Azzaoui R, Corseaux D, Breyne J, Torpier G, Staels B, Van Belle E, Jude B (2009) Tissue factor pathway inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis 204:e4–e14CrossRefGoogle Scholar
  23. 23.
    Kim JA, Chun EJ, Lee MS, Kim KJ, Choi SI (2013) Relationship between amount of cigarette smoking and coronary atherosclerosis on coronary CTA in asymptomatic individuals. Int J Cardiovasc Imaging 29(Suppl 1):21–28CrossRefGoogle Scholar
  24. 24.
    Jia EZ, Liang J, Yang ZJ, Zhu TB, Wang LS, Chen B, Cao KJ, Huang J, Ma WZ (2009) Smoking and coronary atherosclerosis: follow-up study in China. Clin Exp Pharmacol Physiol 36(7):690–695CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Hairong Zhou
    • 1
  • Yanjuan Che
    • 2
  • Xiuhua Fu
    • 2
    Email author
  • Hong Wei
    • 2
  • Xiuying Gao
    • 2
  • Yanxuan Chen
    • 1
  • Shaopeng Zhang
    • 1
  1. 1.Department of General MedicineLonghua District Central HospitalShenzhenChina
  2. 2.Department of Cardiovascular MedicineMudanjiang Second People’s HospitalMudanjiangChina

Personalised recommendations